Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

Personalized Genetic Testing Fails to Improve CRC Screening Rates

  • Leah Lawrence
October 31, 2014
  • Colorectal Cancer, Gastrointestinal Cancer, Gastrointestinal Cancer Targets
Sessile colon polyp
Sessile colon polyp; source: Stephen Holland, MD, Wikimedia Commons.

People at average-risk for colorectal cancer (CRC) who underwent genetic and environmental risk assessment (GERA) to evaluate their risk for CRC were no more likely to undergo CRC screening than those people who did not receive this individualized assessment, results of a study showed.

Additionally, among those people who underwent GERA, those told that they were at elevated risk for CRC were no more likely to undergo screening than those told to be at average risk.

“Further study is required to assess whether other such information and different means of presenting individualized results for common diseases like CRC will spur more healthy behaviors to reduce risk,” researchers led by David S. Weinberg, MD, MSc, of Fox Chase Cancer Center, and colleagues wrote in Annals of Internal Medicine.

In an editorial that accompanied these results, J.S. Blumenthal-Barby, PhD, MA, and Amy L. McGuire, JD, PhD, both of Baylor College of Medicine, and Peter A. Ubel, MD, of Duke University, wrote that these results were surprising and indicate that physicians will need to look beyond genomic medicine to persuade people to participate in practices such as CRC screening.

“We should not look toward personalized medicine and genomics to refine risk estimates in ways that will, on their own, motivate substantial behavior change,” they wrote. “Instead we should utilize such information to identify patients who are most in need of such screening and then rely on proven persuasion techniques to encourage patients to get screened.”

In the study, Weinberg and colleagues randomly assigned 783 patients who were not adherent to screening at study entry to usual care or GERA, which evaluated methylenetetrahydrofolate reductase polymorphisms and serum folate levels. Patients who received GERA were told that they were at either elevated or average risk for CRC.

About one-third of patients in both groups underwent CRC screening within 6 months of study entry (35.7% for usual care vs 33.1% for GERA). Within the GERA group, 38.1% of average-risk patients and 26.9% of elevated-risk patients underwent screening.

The researchers did note an increase in “knowledge about CRC screening and the role of genetic risk, suggesting that the educational component of the intervention was successful.” But they also noted that there was no association between baseline or post-intervention knowledge and the likelihood of a patient undergoing screening.

Related Articles

  • FDA Grants Priority Review to Pemigatinib for Subgroup
  • Risk Tool Shows Promise for Predicting Adverse Opioid-Related Outcomes in Cancer Survivors
  • Active Choice Intervention in EHR Is Effective for Clinician Ordering of Screening Tests
  • What Are the Most Common Esophageal Metastases
  • Circulating Tumor DNA Analysis May Indicate Adjuvant Therapy Efficacy for Stage III CRC

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".